title: Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.
abstract: BACKGROUND
  Cystic fibrosis is a recessive genetic disease characterized by dehydration of the airway surface liquid and impaired mucociliary clearance. As a result, individuals with the disease have difficulty clearing pathogens from the lung and experience chronic pulmonary infections and inflammation. Death is usually a result of respiratory failure. Newly introduced therapies and aggressive management of the lung disease have resulted in great improvements in length and quality of life, with the result that the median expected survival age has reached 36 years. However, as the number of treatments expands, the medical regimen becomes increasingly burdensome in time, money, and health resources. Hence, it is important that treatments should be recommended on the basis of available evidence of efficacy and safety.
  
  
  OBJECTIVE
  The Cystic Fibrosis Foundation therefore established a committee to examine the clinical evidence for each therapy and to provide guidance for the prescription of these therapies.
  
  
  METHODS
  The committee members developed and refined a series of questions related to drug therapies used in the maintenance of pulmonary function. We addressed the questions in one of three ways, based on available evidence: (1) commissioned systematic review, (2) modified systematic review, or (3) summary of existing Cochrane reviews.
  
  
  CONCLUSIONS
  It is hoped that the guidelines provided in this article will facilitate the appropriate application of these treatments to improve and extend the lives of all individuals with cystic fibrosis.
authors.affiliation: Department of Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA. flumepa@musc.edu
authors.forename: Patrick A
authors.initials: PA
authors.lastname: Flume
authors.forename: Brian P
authors.initials: BP
authors.lastname: O'Sullivan
authors.forename: Karen A
authors.initials: KA
authors.lastname: Robinson
authors.forename: Christopher H
authors.initials: CH
authors.lastname: Goss
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Mogayzel
authors.forename: Donna Beth
authors.initials: DB
authors.lastname: Willey-Courand
authors.forename: Janet
authors.initials: J
authors.lastname: Bujan
authors.forename: Jonathan
authors.initials: J
authors.lastname: Finder
authors.forename: Mary
authors.initials: M
authors.lastname: Lester
authors.forename: Lynne
authors.initials: L
authors.lastname: Quittell
authors.forename: Randall
authors.initials: R
authors.lastname: Rosenblatt
authors.forename: Robert L
authors.initials: RL
authors.lastname: Vender
authors.forename: Leslie
authors.initials: L
authors.lastname: Hazle
authors.forename: Kathy
authors.initials: K
authors.lastname: Sabadosa
authors.forename: Bruce
authors.initials: B
authors.lastname: Marshall
mesh_terms: D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002648:Child; D003550:Cystic Fibrosis / Q000188:drug therapy*; D003850:Deoxyribonuclease I / Q000627:therapeutic use; D006801:Humans
chemical_list: D018927:Anti-Asthmatic Agents; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; C085693:DNASE1 protein, human; D003850:Deoxyribonuclease I